Hints and tips:
Related Special Reports
...according to the Food and Drug Administration....
...Robert Barbera, director of the Center for Financial Economics at Johns Hopkins University and another respondent, said the Fed would need to see both steady improvements in inflation and a more significant...
...Leqembi, priced at $26,500 a year, was the first drug with a black-box warning — the most severe designation about possible side effects — to be granted full approval by the US Food and Drug Administration...
...guidance from the Centers for Medicare and Medicaid Services (CMS)....
...Eli Lilly said that it plans to submit the results to the US Food and Drug Administration and other medicine regulators worldwide to seek approval for tirzepatide as a sleep apnoea treatment beginning this...
...Crab, which causes life-threatening illnesses in hospital patients, is classed as a priority concern by the WHO and an urgent threat by the US Centers for Disease Control and Prevention....
...Companies: Frozen potato processor Lamb Weston and consumer packaged foods company Conagra Brands will report earnings results before the bell....
...Food crisis: Trucks filled with tonnes of aid are stuck on Gaza’s border as the Palestinian enclave nears famine. The FT’s latest visual story traces the daily struggle to feed Gaza....
...The US Food and Drug Administration says there is a shortage of Novo Nordisk’s and Eli Lilly’s diabetes drugs, while Belgium has banned the off-label use of Novo Nordisk’s diabetes drug for obesity treatments...
...Rafael Fernández de Castro, director of the Center for US-Mexican Studies at UC San Diego, said: “This government . . . reacts [to the DEA] with more emphasis on sovereignty — and that creates clashes....
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
...The US Food and Drug Administration recently approved the first-ever drug designed specifically for the most common liver disease, metabolic dysfunction-associated steatohepatitis or mash, developed by Madrigal...
...The US Food and Drug Administration on Friday approved the world’s first ever two gene therapies to treat patients with sickle cell disease....
...A decision on Eli Lilly’s donanemab drug from the US Food and Drug Administration was originally due by the end of the first quarter, but the medicine will now be subject to a further review by an advisory...
...Huge demand for GLP-1s, the lucrative new class of diabetes and weight-loss drugs that include Wegovy and Zepbound, is testing the capacity of plants capable of producing and administering the drug. 4....
...Chart of the day Africa had to import $43bn of food in 2019, and the World Bank estimates it could rise to $110bn by next year....
...The latest figures for the world’s largest economies show that inflation remains elevated in some countries, excluding food and energy, a key measure of underlying price pressures....
...Brian Lian, Viking’s chief executive, said the company would meet regulators at the US Food and Drug Administration to assess next steps by the middle of the year....
...Jessica SmithI’m Jessica Smith, in for Marc Filippino, and here’s the news you need to start your day....
...Monetary policy: Federal Reserve Bank of Atlanta president Raphael Bostic appears at an event hosted by the University of Cincinnati’s Real Estate Center....
...hit by the two-year surge in food costs....
...anguish of losing their child,” said Bennett Smith, Orchard’s senior vice-president and general manager of North America....
...The model is rarely used in continental Europe, however, while in the US it is mainly confined to niches such as fast-food franchises rather than essential utilities....
...These will be the first results from a study designed around landmark US Food and Drug Administration guidelines for researching psychedelics that were outlined last year, a decision that encouraged investors...
...Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs. Read the full interview....
International Edition